1607005-13-9

Upstream product

• 106-38-7 para-bromotoluene 
• 271-70-5 7H-pyrrolo[2,3-d]pyrimidine 
• 5720-05-8 4-methylphenylboronic acid 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 4294-57-9 para-methylphenylmagnesium bromide 

Relevant academic research and scientific papers

Method for catalytically synthesizing 7-denitrified purine compound by using iron coordination compound

The invention relates to a method for catalytically synthesizing a 7-denitrogenated purine compound by using an iron coordination compound. The method comprises the following steps: in the presence of an alkali, taking 7-denitrogenated purine and halogenated hydrocarbon as raw materials, taking an iron coordination compound containing an ortho-carborane benzoxazole structure as a catalyst, and reacting at room temperature to obtain the 6-substituted 7-denitrogenated purine compound. Compared with the prior art, the method has the advantages that the iron coordination compound containing the ortho-carborane benzoxazole structure is utilized to catalytically synthesize the 6-substituted 7-deazapurine compound, so that the compound is prepared by a one-pot method at room temperature, the use equivalent of the catalyst is low, the reaction condition is mild, the raw materials are cheap and easy to obtain, the substrate universality is high, and the yield is high.

NOVEL 6-SUBSTITUTED 7-DEAZAPURINES AND CORRESPONDING NUCLEOSIDES AS MEDICAMENTS

The present invention relates to the synthesis of 6-substituted 7-deazapurines and their corresponding nucleosides by coupling aryl or alkyl Grignard reagents with halogenated purine nucleosides in the presence of iron or an iron/copper mixture such as Fe(acac)3/Cul. The present invention also relates to pharmaceutical compositions comprising said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections.

Synthesis and biological evaluation of selected 7H-pyrrolo[2,3-d]pyrimidine derivatives as novel CDK9/CyclinT and Haspin inhibitors

Protein kinases, including CDK9/CyclinT and Haspin, are regarded as potential drug targets in cancer therapy. Findings from a previous study suggested 7-azaindole as a privileged scaffold for producing inhibitors of CDK9/CyclinT and Haspin. Inspired by these findings, the current study synthesised and evaluated thirteen (13) C6-substituted 7-azaindole and twenty (20) C4-substituted structurally related 7H-pyrrolo[2,3-d]pyrimidine derivatives against a panel of protein kinases, including CDK9/CyclinT and Haspin. Eleven of the 7H-pyrrolo[2,3-d]pyrimidine derivatives exhibited activity toward CDK9/CyclinT, while 4 of compounds had activity against Haspin. The best CDK9/CyclinT (IC50 of 0.38 μM) and Haspin (IC50 of 0.11 μM) activities were achieved by compounds 7d and 7f, respectively. Hence, these compounds may be valuable starting points for development of new anti-cancer drugs.

Iron/Copper Co-Catalyzed Cross-Coupling Reaction for the Synthesis of 6-Substituted 7-Deazapurines and the Corresponding Nucleosides

An efficient access to 6-substituted 7-deazapurine and the corresponding nucleosides by coupling aryl or alkyl Grignard reagents and halogenated purine nucleosides in the presence of Fe(acac)3/CuI is described. A series of 6-substituted 7-deazapurines and the corresponding nucleosides were obtained in medium to good yields. For the synthesis of modified nucleosides that will be the subject of biological testing, we propose to use iron-catalyzed instead of palladium-catalyzed reaction. The synthesized compounds were tested for their antiproliferative activity. The cytotoxicity study of compounds 11a-q shows that by modifying the 6-position of 7-deazapurine ribonucleosides, the compounds may become selective for certain cancer cell lines.

INHIBITORS OF BRUTON'S TYROSINE KINASE

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with exc